View this email in your browser

PLOS ONE

Congratulations Tetsuya!

Your article is among the top 10% most cited *PLOS ONE* papers published in 2016.

Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics

CITED 22 TIMES
as of September 19, 2019.
#PLOSMOSTCITED | #PLOSONEAUTHOR | SHARE THIS

When you choose Open Science, your work is freely available for anyone, anywhere to access, read, cite and reuse with attribution, maximizing the potential impact of your research.

MEASURE YOUR IMPACT
Track views, downloads and citations across PLOS and PMC with your personal Article Level Metrics (ALMs).

Thank you for being a part of the *PLOS ONE* community. Every PLOS article is a collaboration between editorial boards, staff editors, reviewers and authors, working across time zones, career stages and disciplines to evaluate, share and advance science.

YOU'RE IN GOOD COMPANY
PLOS ONE is home to rigorous original research from the natural sciences, medical research, engineering, as well as the related social sciences and humanities.

Thank you for choosing Open Science!

With best wishes,

Joerg Heber, Editor-in-Chief, *PLOS ONE*
ORCID: 0000-0002-6370-4254

Sign up to receive future updates from PLOS, including researcher news, events, Calls for Papers and more.

STAY UP TO DATE

Unsubscribe | Update Profile